J.-M. Nabholtz

953 total citations
24 papers, 742 citations indexed

About

J.-M. Nabholtz is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J.-M. Nabholtz has authored 24 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J.-M. Nabholtz's work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (7 papers). J.-M. Nabholtz is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (7 papers). J.-M. Nabholtz collaborates with scholars based in Canada, France and United States. J.-M. Nabholtz's co-authors include P. Fumoleau, M. Namer, Benjamin Winograd, G. Catimel, M. Spielmann, M. Bontenbal, Pierfranco Conté, Jacques Bonneterre, Karen A. Gelmon and U. Klaassen and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and The Oncologist.

In The Last Decade

J.-M. Nabholtz

23 papers receiving 711 citations

Peers

J.-M. Nabholtz
Devika Gajria United States
Rubi K. Li Philippines
M. Piccart Belgium
Giuseppe Gullo Ireland
B. Lisboa Germany
Michael E. Menefee United States
G. Konecny Germany
S. Johnston United Kingdom
G Mariani Italy
Leslie Smetzer United States
Devika Gajria United States
J.-M. Nabholtz
Citations per year, relative to J.-M. Nabholtz J.-M. Nabholtz (= 1×) peers Devika Gajria

Countries citing papers authored by J.-M. Nabholtz

Since Specialization
Citations

This map shows the geographic impact of J.-M. Nabholtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-M. Nabholtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-M. Nabholtz more than expected).

Fields of papers citing papers by J.-M. Nabholtz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.-M. Nabholtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-M. Nabholtz. The network helps show where J.-M. Nabholtz may publish in the future.

Co-authorship network of co-authors of J.-M. Nabholtz

This figure shows the co-authorship network connecting the top 25 collaborators of J.-M. Nabholtz. A scholar is included among the top collaborators of J.-M. Nabholtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-M. Nabholtz. J.-M. Nabholtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paget‐Bailly, Sophie, P. Fumoleau, Gilles Romieu, et al.. (2018). Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. The Breast. 41. 1–7. 8 indexed citations
2.
Pivot, Xavier, Thomas Suter, J.-M. Nabholtz, et al.. (2015). Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. European Journal of Cancer. 51(13). 1660–1666. 49 indexed citations
3.
Nabholtz, J.-M., Marie‐Ange Mouret‐Reynier, V. Servent, et al.. (2013). Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study.. Journal of Clinical Oncology. 31(15_suppl). 1057–1057. 5 indexed citations
4.
Mahammedi, Hakim, E. Planchat, H. Curé, et al.. (2011). Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC).. Journal of Clinical Oncology. 29(15_suppl). e15069–e15069. 1 indexed citations
5.
6.
André, Fabrice, Kristine Broglio, Lajos Pusztai, et al.. (2010). Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. The Oncologist. 15(5). 476–483. 5 indexed citations
7.
Jouannaud, Christelle, J. Charpentier, Jean-Christophe Eymard, et al.. (2010). Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence.. Journal of Clinical Oncology. 28(15_suppl). 620–620. 1 indexed citations
8.
Nabholtz, J.-M.. (2008). Long-term safety of aromatase inhibitors in the treatment of breast cancer. Therapeutics and Clinical Risk Management. Volume 4(1). 189–204. 51 indexed citations
9.
Nabholtz, J.-M. & Joseph Gligorov. (2006). The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer. Reviews on Recent Clinical Trials. 1(3). 237–249. 5 indexed citations
10.
Nabholtz, J.-M., Scott North, Michael Smylie, et al.. (2000). Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.. PubMed. 27(2 Suppl 3). 11–8. 26 indexed citations
11.
Skillings, Jamey, J.-M. Nabholtz, C. Sawka, et al.. (1999). An epidemiological review of red cell transfusions in cancer chemotherapy.. PubMed. 3(3). 207–12. 15 indexed citations
12.
Nabholtz, J.-M., John R. Mackey, Alexander Paterson, et al.. (1998). Final results of a phase II study of Taxotere (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in thétreatment of metastatic breast cancer (MBC). European Journal of Cancer. 34. S43–S43. 1 indexed citations
13.
Nabholtz, J.-M., John R. Mackey, Alexander Paterson, et al.. (1997). Taxotere™ (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC). European Journal of Cancer. 33. S146–S146. 4 indexed citations
14.
Nabholtz, J.-M., W.R. Bezwoda, David Melnychuk, et al.. (1997). Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.. PubMed. 11(8 Suppl 8). 25–30. 31 indexed citations
15.
Nabholtz, J.-M., Michael Smylie, John R. Mackey, et al.. (1997). Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.. PubMed. 11(6 Suppl 6). 25–41. 24 indexed citations
16.
Nabholtz, J.-M., John R. Mackey, Michael Smylie, et al.. (1997). P953. Phase II study of taxotere® (Docetaxel, D), Doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC). The Breast. 6(5). 343–344. 5 indexed citations
17.
Nabholtz, J.-M., Karen A. Gelmon, M. Bontenbal, et al.. (1996). Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.. Journal of Clinical Oncology. 14(6). 1858–1867. 331 indexed citations
18.
Skillings, Jamey, J.-M. Nabholtz, C. Sawka, et al.. (1995). 879 An epidemiological review of anaemia in cancer chemotherapy in Canada. European Journal of Cancer. 31. S183–S183. 7 indexed citations
19.
MacLean, Grant D., R. Rao Koganty, Ting C. Wong, et al.. (1993). Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunology Immunotherapy. 36(4). 215–222. 155 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Devika Gajria Breakdown of academic impact, for papers by Rubi K. Li Breakdown of academic impact, for papers by M. Piccart Breakdown of academic impact, for papers by Giuseppe Gullo Breakdown of academic impact, for papers by B. Lisboa Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by G. Konecny Breakdown of academic impact, for papers by S. Johnston Breakdown of academic impact, for papers by G Mariani Breakdown of academic impact, for papers by Leslie Smetzer
Rankless by CCL
2026